| Literature DB >> 21367607 |
T Andoh1, T Fujimoto, T Sudo, I Fujita, M Imabori, H Moritake, T Sugimoto, Y Sakuma, T Takeuchi, S Kawabata, M Kirihata, T Akisue, K Yayama, M Kurosaka, S Miyatake, Y Fukumori, H Ichikawa.
Abstract
Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake l-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of (10)B (45-74 ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of L-BPA-fructose complex (500 mg BPA/kg). Copyright ÂEntities:
Mesh:
Substances:
Year: 2011 PMID: 21367607 DOI: 10.1016/j.apradiso.2011.02.005
Source DB: PubMed Journal: Appl Radiat Isot ISSN: 0969-8043 Impact factor: 1.513